---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-024532"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-07-14T23:59:59+00:00"
generated_at: "2026-06-13T08:13:15.809681+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Oncocyte amends CEO employment agreement; removes 800,000-share performance option grant

## Summary
- CEO Joshua Riggs' 800,000-share performance option grant eliminated under amendment dated July 13, 2023.
- Company may grant new performance-based options if shareholders approve plan amendment to remove annual individual limit.
- Amendment also modifies equity vesting acceleration provisions for time-based awards in certain termination scenarios.
- Base salary remains $360,000; target bonus unchanged at 50% of base salary.

## SEC filing metadata
- accession: 0001493152-23-024532
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-07-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223024532/0001493152-23-024532-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223024532/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-024532
- JSON: https://secwatch.observer/filing/0001493152-23-024532.json
- Plain text: https://secwatch.observer/filing/0001493152-23-024532.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.